Repeated Examinations for Typing Pulmonary Embolism

Recruiting now

Conditions studied: Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute, Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism With Right Ventricle Enlargement, Pulmonary Embolism (PE)

In brief

PURPOSE The two related purposes of the RE-TyPE study are: 1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and 2. To establish a platform for longitudinal follow-up for all pulmonary embolism at Sahlgrenska University Hospital HYPOTHESES 1. The dynamic pattern of change, evaluated thorough repeated measures of biomarkers, electrocardiography and echocardiography during the first 48 hours after pulmonary embolism, better predicts outcome than static measurements currently used to predict outcome 2. Establishment of a platform for longitudinal follow-up will improve quality of care and outcome for patients with pulmonary embolism at Sahlgrenska University Hospital

Key facts

Study ID

NCT07491094

Run by

Sahlgrenska University Hospital

People needed

400

Starts

2026-04-01

Expected to finish

2032-01-01

Last updated by the study team

2026-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital
• Written informed consent
• Exclusion Criteria from Cohort A:
• Low risk, intermediate-low risk or high risk PE*
• >48 hours since arrival to hospital
• Expected inability to comply with the protocol (e.g. dementia)
• There are no exclusion criteria from Cohort B. Patients in Cohort B who are not part of Cohort A may be included at diagnosis (day 0) or at follow-up (\~day 90).
• If biomarkers (and/or echocardiography) are not available in hemodynamically stable patients, RV/LV-ratio >1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B

Where it is running

• Sahlgrenska University Hospital/Sahlgrenska — Gothenburg, Region Västra Götaland, Sweden (enrolling)
• Sahlgrenska University Hospital/Mölndal — Gothenburg, Region Västra Götaland, Sweden
• Sahlgrenska University Hospital/Östra — Gothenburg, Region Västra Götaland, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.